Welcome to Iris Biotech
For better service please confirm your country and language we detected.
Currency
USD
Blog
-
Product of the Month: Novel Fmoc-Amino Acids for Convenient Access to HDAC Inhibitors
Find out more about those building blocks with side chains able to coordinate metal ions, and why peptide-based HDACis are intriguing synthetic targets.
read more
-
His-Tag for Specific Linker Attachment
Learn, how His-Tag can be used for specific linker attachment. Another example in our LINKEROLOGY series of sophisticated linker technologies.
read more
-
Iris Biotech joins „BIOPARK8-Brain-Network“
We, Iris Biotech GmbH, are pleased that Dr. Thomas Bruckdorfer completes the BIOPARK8-Brain-Network in Regensburg and will enrich it with our experience.
read more
-
Product Focus: TT-232, a Potent Somatostatin Analogue
Amongst various somatostatin analogues, the pentacyclic heptapeptide TT-232 bears unique properties. Iris Biotech offers TT-232 as triacetate and trifluoroacetate salt, respectively, as well as conjugated to either biotin or the fluorophore indocyanine green.
read more
-
New Collaboration with SciClix
Find out more about our partner SciClix from Singapore and our new collaboration!
read more
-
Identification and Quantification of Maillard RPs
Find out which Maillard Reaction Products from Iris Biotech were used in the development of a state-of-the-art analytical method for 15 different AGEs.
read more
-
Peptide Easy Clean (PEC): now distributed in India
Now in India available: the Belyntic Kits Peptide Easy Clean (PEC)
read more
-
Product of the Month: cyclo-Arg-Gly-Asp (RGD) Peptides
The integrin receptor interacting RGD sequence and related peptides act as promising tools for drug therapy and cancer research. Find more information on our portfolio of cyclic RGD peptides.
read more
-
L-Cysteine from non-human/non-animal origin
Iris Biotech offers L-Cysteine Hydrochloride Monohydrate from Cystine, which is produced by fermentation of Escherichia coli.
read more
-
Statement on COVID-19
Beginning of March 2020 Iris Biotech implemented measures in order to minimize the impact of and the risks associated with the current pandemic. As of 26 March 2020, Iris Biotech is classified as system-relevant.
read more
